Literature DB >> 22172322

Risk for human African trypanosomiasis, Central Africa, 2000-2009.

Pere P Simarro1, Giuliano Cecchi, José R Franco, Massimo Paone, Eric M Fèvre, Abdoulaye Diarra, José Antonio Ruiz Postigo, Raffaele C Mattioli, Jean G Jannin.   

Abstract

Comprehensive georeference records for human African trypanosomiasis in Cameroon, Central African Republic, Chad, Congo, Equatorial Guinea, and Gabon were combined with human population layers to estimate a kernel-smoothed relative risk function. Five risk categories were mapped, and ≈3.5 million persons were estimated to be at risk for this disease.

Entities:  

Mesh:

Year:  2011        PMID: 22172322      PMCID: PMC3311175          DOI: 10.3201/eid1712.110921

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


The most recent continental estimates of persons at risk for human African trypanosomiasis (HAT), also known as sleeping sickness, were published by the World Health Organization in 1998 (). These estimates were provided on a country-by-country basis, and they were largely based on educated guesses and rough estimations of experts. Since that time, major progress has been made in HAT control and surveillance (). Data collection and reporting have also substantially improved and increasingly include an explicit and accurate mapping component (–). The magnitude of the recent advances in HAT control and surveillance is such that up-to-date estimates of the number and distribution of persons at risk are urgently needed. The purpose of this study was to develop a method to estimate and map the risk for HAT in central Africa.

The Study

The study area in central Africa comprised Cameroon, Central African Republic, Chad, Congo, Equatorial Guinea, and Gabon. The Gambian form of sleeping sickness caused by Trypanosoma brucei gambiense is endemic to these 6 countries. Reported cases for 2000–2009 were obtained from the Atlas of HAT (). This Atlas provided mapped data at the village level for 15,083 (94.2%) of 16,005 cases of HAT reported in the study region. Average mapping accuracy for these cases was ≈800 m (). For the remaining 5.8% of cases, village-level information was unavailable, but the focus of geographic origin was known. Therefore, these cases were distributed among the disease-endemic villages of their focus by using proportional allocation, whereby proportionally more unmapped cases were attributed to mapped villages that reported more cases during the study period. Human population distribution was obtained from LandScan databases (www.ornl.gov/sci/landscan). LandScan provides global grids in which census counts are allocated to grid nodes by probability coefficients (,). Probability coefficients were based on land cover, elevation, slope, roads, and populated areas/points. LandScan spatial resolution is <1 km at the equator, and population layers are updated yearly. To delineate risk areas, an average of all LandScan population layers during 2000–2009 was used. Subsequently, LandScan 2009 data were combined with the risk map to provide estimates of persons at risk at the end of the study period. Both input layers (i.e., HAT cases and LandScan human population) can be regarded as spatial point processes, thus amenable to spatial smoothing (). Smoothing results in intensity surfaces where the intensity of a point process is the mean number of events per unit area (). For this study, the intensity of HAT cases and human population was estimated by using a quadratic kernel function (). Intensity surfaces were generated by using the same search radius (), which was set at 30 km. Before spatial smoothing, the number of HAT cases reported in 2000–2009 was divided by 10 to yield the average number of cases per year. All LandScan layers from 2000 through 2009 were also averaged and subsequently converted from grid (raster format) to points (vector format) to enable spatial smoothing. No attempt was made to account for edge effects of smoothing (), but edge effects were not expected to matter unduly because our final objective was to estimate the ratio of 2 intensities (). Spatial smoothing resulted in 2 surfaces, D(x,y) and P(x,y), which represented average annual estimates of disease intensity and population intensity, respectively. A relative risk function R(x,y) could subsequently be estimated as the ratio D(x,y)/P(x,y). Thresholds were applied to the function R(x,y) to distinguish 5 categories of risk ranging from very high to very low (Table 1). When R(x,y) was <1 HAT case/million persons/year, risk was considered marginal.
Table 1

Thresholds for definition of risk for human African trypanosomiasis, central Africa, 2000–2009

CategoryNo. cases/inhabitants/y
Very high>1/102
High<1/102 to >1/103
Moderate<1/103 to >1/104
Low<1/104 to >1/105
Very low<1/105 to >1/106
The results of the analysis are shown in the Figure, in which risk areas are mapped, and in Table 2, which summarizes the number of persons at risk, the extent of areas at risk, and the corresponding number of cases. In the 6 countries studied, ≈3.5 million persons are estimated to be at risk for contracting HAT (8.9% of the total population), distributed over an area of 224,000 km2 (7.5% of the total land area).
Figure

Lambert azimuthal equal-area projection (www.quadibloc.com/maps/maz0204.htm) of risk for infection with Trypanosoma brucei gambiense, central Africa, 2000–2009.

Table 2

Estimated risk for infection with Trypanosoma brucei gambiense in 6 countries, central Africa, 2000–2009*

CountryRisk category
Total
Very highHighModerateLowVery low
Cameroon0 (0); 00 (0); 028 (22); 97236 (80); 87366 (71); 1630 (172); 185
Central African Rep29 (59); 6,07533 (123); 1,193115 (212); 287133 (140); 2865 (78); 0374 (612); 7,583
Chad0 (0); 0109 (33); 2,884110 (34); 76120 (34); 19119 (36); 1458 (137); 2,980
Congo3 (16); 1,250105 (205); 2,266479 (367); 1,169443 (337); 68138 (164); 31,168 (1,089); 4,756
Equatorial Guinea0 (0); 02 (4); 4227 (37); 1308 (16); 14 (8); 040 (65); 173
Gabon0 (0); 02 (6); 16121 (58); 11619 (69); 24762 (36); 27804 (168); 328
Total32 (74); 7,325251 (372); 6,546780 (730); 1,875959 (675); 2271,453 (392); 323,475 (2,244); 16,005

*Values are no. persons x 103 at risk (area in km2 × 102 at risk); no. cases of human African trypanosomiasis. Risk categories are defined in Table 1. Rep, Republic.

Lambert azimuthal equal-area projection (www.quadibloc.com/maps/maz0204.htm) of risk for infection with Trypanosoma brucei gambiense, central Africa, 2000–2009. *Values are no. persons x 103 at risk (area in km2 × 102 at risk); no. cases of human African trypanosomiasis. Risk categories are defined in Table 1. Rep, Republic. Very high-risk areas comprise the most active foci in the Central African Republic (Batangafo, Obo, Mboki, and Zemio) and in Congo (Mpouya and Ngabé). These zones are located mainly in rural areas in which human population density is low, but they also include a few small towns. Areas included in the high-risk category are in foci in Bodo (Chad); Maitikoulou and Djemah (Central African Republic); Noya (Gabon); Kogo (Equatorial Guinea); and Loukoléla, Mossaka, Ignié, and Loudima (Congo). High-risk zones are also located around very high–risk areas. The moderate-risk category includes foci in Nola-Bilolo and Lobaye Prefecture (Central African Republic), Bipindi and Campo (Cameroon), Kango and Port Gentil (Gabon), Mbini (Equatorial Guinea), and areas in Bouenza and Gamboma (Congo). Low-risk areas were found mainly at the periphery of zones to which HAT is highly endemic, but they also include a few isolated foci with low levels of transmission, such as Mamfé, Fontem, and Doumé (Cameroon). Very low­–risk zones represent the extreme periphery of active foci, but they also include isolated rural foci, such as Mbandjock (Cameroon) and Libreville (Gabon), one of the largest urban agglomerations in the region.

Conclusions

The methods reported provide an evidence-based approach to mapping the risk for HAT and estimating at-risk population. The use of different risk categories enables severity of the disease to be ranked. We did not attempt to model underascertainment and underreporting, which are known to affect a neglected disease such as HAT. However, recent progress in the fields of active and passive surveillance () and comprehensive and systematic collection and mapping of HAT data over a 10-year period () substantially contributed to the robustness of the presented risk estimates. At the same time, we highlight that further improvements in consistency and coverage of HAT case detection and reporting are needed and require long-term efforts. Because of the novel approach used in this study, it is unwarranted to make comparisons with previous figures of at-risk population, especially if the goal is to explore trends. Conversely, use of global human population layers and regular updating of the Atlas of HAT will enable future trends to be captured and the method to be applied to all countries to which HAT is endemic. The type of risk maps presented will help target the most appropriate, site-specific strategies for HAT control and surveillance, such as the optimal frequency of active screening activities (). These maps will enable limited resources available to be allocated rationally and where they are needed most.
  9 in total

1.  An application of density estimation to geographical epidemiology.

Authors:  J F Bithell
Journal:  Stat Med       Date:  1990-06       Impact factor: 2.373

2.  The Atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases.

Authors:  Pere P Simarro; Giuliano Cecchi; Massimo Paone; José R Franco; Abdoulaye Diarra; José A Ruiz; Eric M Fèvre; Fabrice Courtin; Raffaele C Mattioli; Jean G Jannin
Journal:  Int J Health Geogr       Date:  2010-11-01       Impact factor: 3.918

3.  The elimination of Trypanosoma brucei gambiense sleeping sickness in the focus of Luba, Bioko Island, Equatorial Guinea.

Authors:  P P Simarro; J R Franco; P Ndongo; E Nguema; F J Louis; J Jannin
Journal:  Trop Med Int Health       Date:  2006-05       Impact factor: 2.622

Review 4.  Control and surveillance of African trypanosomiasis. Report of a WHO Expert Committee.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1998

Review 5.  Human African trypanosomiasis in non-endemic countries (2000-2010).

Authors:  Pere P Simarro; José R Franco; Giuliano Cecchi; Massimo Paone; Abdoulaye Diarra; José A Ruiz Postigo; Jean G Jannin
Journal:  J Travel Med       Date:  2011-12-08       Impact factor: 8.490

6.  Mapping sleeping sickness in Western Africa in a context of demographic transition and climate change.

Authors:  G Cecchi; F Courtin; M Paone; A Diarra; J R Franco; R C Mattioli; P P Simarro
Journal:  Parasite       Date:  2009-06       Impact factor: 3.000

7.  The human African trypanosomiasis control and surveillance programme of the World Health Organization 2000-2009: the way forward.

Authors:  Pere P Simarro; Abdoulaye Diarra; Jose A Ruiz Postigo; José R Franco; Jean G Jannin
Journal:  PLoS Negl Trop Dis       Date:  2011-02-22

8.  Towards the Atlas of human African trypanosomiasis.

Authors:  Giuliano Cecchi; Massimo Paone; José R Franco; Eric M Fèvre; Abdoulaye Diarra; José A Ruiz; Raffaele C Mattioli; Pere P Simarro
Journal:  Int J Health Geogr       Date:  2009-03-18       Impact factor: 3.918

Review 9.  Eliminating human African trypanosomiasis: where do we stand and what comes next?

Authors:  Pere P Simarro; Jean Jannin; Pierre Cattand
Journal:  PLoS Med       Date:  2008-02       Impact factor: 11.069

  9 in total
  18 in total

Review 1.  Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis.

Authors:  Advait S Nagle; Shilpi Khare; Arun Babu Kumar; Frantisek Supek; Andriy Buchynskyy; Casey J N Mathison; Naveen Kumar Chennamaneni; Nagendar Pendem; Frederick S Buckner; Michael H Gelb; Valentina Molteni
Journal:  Chem Rev       Date:  2014-11-03       Impact factor: 60.622

2.  In vitro and in vivo evaluation of 28DAP010, a novel diamidine for treatment of second-stage African sleeping sickness.

Authors:  Tanja Wenzler; Sihyung Yang; Donald A Patrick; Olivier Braissant; Mohamed A Ismail; Richard R Tidwell; David W Boykin; Michael Zhuo Wang; Reto Brun
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

3.  Pharmacokinetics, Trypanosoma brucei gambiense efficacy, and time of drug action of DB829, a preclinical candidate for treatment of second-stage human African trypanosomiasis.

Authors:  Tanja Wenzler; Sihyung Yang; Olivier Braissant; David W Boykin; Reto Brun; Michael Zhuo Wang
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

Review 4.  Glossina fuscipes populations provide insights for human African trypanosomiasis transmission in Uganda.

Authors:  Serap Aksoy; Adalgisa Caccone; Alison P Galvani; Loyce M Okedi
Journal:  Trends Parasitol       Date:  2013-07-08

5.  Diversity of human African trypanosomiasis epidemiological settings requires fine-tuning control strategies to facilitate disease elimination.

Authors:  P P Simarro; J R Franco; A Diarra; J A Ruiz Postigo; J Jannin
Journal:  Res Rep Trop Med       Date:  2013-02-04

Review 6.  Large-scale spatial population databases in infectious disease research.

Authors:  Catherine Linard; Andrew J Tatem
Journal:  Int J Health Geogr       Date:  2012-03-20       Impact factor: 3.918

7.  Estimating and mapping the population at risk of sleeping sickness.

Authors:  Pere P Simarro; Giuliano Cecchi; José R Franco; Massimo Paone; Abdoulaye Diarra; José Antonio Ruiz-Postigo; Eric M Fèvre; Raffaele C Mattioli; Jean G Jannin
Journal:  PLoS Negl Trop Dis       Date:  2012-10-25

8.  Human African trypanosomiasis in the Democratic Republic of the Congo: disease distribution and risk.

Authors:  Crispin Lumbala; Pere P Simarro; Giuliano Cecchi; Massimo Paone; José R Franco; Victor Kande Betu Ku Mesu; Jacquies Makabuza; Abdoulaye Diarra; Shampa Chansy; Gerardo Priotto; Raffaele C Mattioli; Jean G Jannin
Journal:  Int J Health Geogr       Date:  2015-06-06       Impact factor: 3.918

9.  Monitoring the Progress towards the Elimination of Gambiense Human African Trypanosomiasis.

Authors:  Pere P Simarro; Giuliano Cecchi; José R Franco; Massimo Paone; Abdoulaye Diarra; Gerardo Priotto; Raffaele C Mattioli; Jean G Jannin
Journal:  PLoS Negl Trop Dis       Date:  2015-06-09

Review 10.  Genetic dissection of drug resistance in trypanosomes.

Authors:  Sam Alsford; John M Kelly; Nicola Baker; David Horn
Journal:  Parasitology       Date:  2013-04-03       Impact factor: 3.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.